Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma.

Nature communications - 7 Dec 2020

Ribas Antoni, Algazi Alain, Ascierto Paolo A, Butler Marcus O, Chandra Sunandana, Gordon Michael, Hernandez-Aya Leonel, Lawrence Donald, Lutzky Jose, Miller Wilson H, Campbell Katie M, Delafont Bruno, Marshall Shannon, Mueller Nancy, Robert Caroline

Abstract excerpt

Combining PD-L1 blockade with inhibition of oncogenic mitogen-activated protein kinase (MAPK) signaling may result in long-lasting responses in patients with advanced melanoma. This phase 1, open-label, dose-escalation and -expansion study (NCT02027961) investigated safety, tolerability and preliminary efficacy of durvalumab (anti-PD-L1) combined with dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to B7-H1 Antigen
Share to Diarrhea

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Exanthema

Share to Imidazoles

Share to Oximes

Share to Progression-Free Survival

Share to Pyridones

Share to Pyrimidinones

Source

Open in PubMed Open full text

Identifiers

PMID: 33288749
DOI: 10.1038/s41467-020-19810-w
PMCID: PMC7721806

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma.PMID 33288749Read ↗

BRAF plus MEK-targeted drugs: a new standard of treatment for BRAF-mutant advanced melanoma.Semantic proximity Read ↗

MEK inhibitors for the treatment of NRAS mutant melanoma.Semantic proximity Read ↗

IMPemBra: a phase 2 study comparing pembrolizumab with intermittent/short-term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 mutation.Semantic proximity Read ↗

Combination dabrafenib and trametinib in the management of advanced melanoma with BRAFV600 mutations.Semantic proximity Read ↗

Trametinib in the treatment of melanoma.Semantic proximity Read ↗

Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma.Semantic proximity Read ↗

Phase II Clinical Trial of Trametinib and Low-Dose Dabrafenib in Advanced, Previously Treated BRAFV600/NRASQ61 Wild-Type Melanoma (TraMel-WT)Semantic proximity Read ↗

Future of combination therapy with dabrafenib and trametinib in metastatic melanoma.Semantic proximity Read ↗

Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations.Semantic proximity Read ↗

BRAF and NRAS Mutation Status and Response to Checkpoint Inhibition in Advanced Melanoma.Semantic proximity Read ↗

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.Semantic proximity Read ↗

Dabrafenib for the treatment of melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.